Precursor-directed biosynthesis of 12-ethyl erythromycin.
A precursor-directed method for the biosynthesis of novel 6-deoxyerythronolide B derivatives has been extended to allow alteration of the functionality at C-12. We recently described a simple and practical method for harnessing the biosynthetic potential of the erythromycin pathway to generate novel molecules of natural product-like complexity by feeding designed synthetic molecules to an engineered mutant strain having an altered 6-deoxyerythronolide B synthase (DEBS). Our initial applications of this technique focused on alteration of the ethyl side chain of 6-dEB (C14-C15). We now report the extension of this approach to modification of the C-12 substituent. An appropriately designed substrate is shown to incorporate into 6-dEB biosynthesis, yielding a 6-dEB analogue bearing a 12-ethyl group. This 6-dEB analogue is a substrate for post-polyketide tailoring enzymes, and is converted into the corresponding analogue of erythromycin C. These results show that many of the downstream active sites are tolerant of this unnatural functionality and suggest that a wide variety of erythromycin derivatives should be accessible by this approach or by total biosynthesis via genetic engineering.
Jacobsen
J R
JR
Department of Chemical Engineering, Stanford University, CA 94305-5025, USA.
Keatinge-Clay
A T
AT
Cane
D E
DE
Khosla
C
C
D000900:Anti-Bacterial Agents / Q000096:biosynthesis*; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000096:biosynthesis*; D009097:Multienzyme Complexes / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D016930:Saccharopolyspora / Q000201:enzymology / Q000235:genetics; D013302:Streptomyces / Q000201:enzymology / Q000235:genetics
C116209:12-desmethyl-12-ethyl-6-deoxyerythronolide; D000900:Anti-Bacterial Agents; D009097:Multienzyme Complexes; C034277:6-deoxyerythronolide B; D004917:Erythromycin